68 related articles for article (PubMed ID: 2143389)
21. Stereospecific deuterium substitution at the alpha-carbon position of dopamine and its effect on oxidative deamination catalyzed by MAO-A and MAO-B from different tissues.
Yu PH; Bailey BA; Durden DA; Boulton AA
Biochem Pharmacol; 1986 Mar; 35(6):1027-36. PubMed ID: 3954792
[TBL] [Abstract][Full Text] [Related]
22. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion.
Gal S; Zheng H; Fridkin M; Youdim MB
J Neurochem; 2005 Oct; 95(1):79-88. PubMed ID: 16181414
[TBL] [Abstract][Full Text] [Related]
23. Role of chronic inhibition of dopamine-metabolizing enzymes in the regulation of renal sodium and phosphate excretion in the rat remnant kidney.
Sampaio-Maia B; Moreira-Rodrigues M; Pestana M
Nephron Physiol; 2006; 103(1):p14-24. PubMed ID: 16352914
[TBL] [Abstract][Full Text] [Related]
24. SL25.1131 [3(S),3a(S)-3-methoxymethyl-7-[4,4,4-trifluorobutoxy]-3,3a,4,5-tetrahydro-1,3-oxazolo[3,4-a]quinolin-1-one], a new, reversible, and mixed inhibitor of monoamine oxidase-A and monoamine oxidase-B: biochemical and behavioral profile.
Aubin N; Barneoud P; Carter C; Caille D; Sontag N; Marc C; Lolivier J; Gardes A; Perron C; Le Kim A; Charieras T; Pandini M; Burnier P; Puech F; Jegham S; George P; Scatton B; Curet O
J Pharmacol Exp Ther; 2004 Sep; 310(3):1171-82. PubMed ID: 15178694
[TBL] [Abstract][Full Text] [Related]
25. Inhibition potential of 3,4-methylenedioxymethamphetamine (MDMA) and its metabolites on the in vitro monoamine oxidase (MAO)-catalyzed deamination of the neurotransmitters serotonin and dopamine.
Steuer AE; Boxler MI; Stock L; Kraemer T
Toxicol Lett; 2016 Jan; 243():48-55. PubMed ID: 26721607
[TBL] [Abstract][Full Text] [Related]
26. The presence of the type A form of monoamine oxidase within nigrostriatal dopamine-containing neurons.
Demarest KT; Smith DJ; Azzaro AJ
J Pharmacol Exp Ther; 1980 Nov; 215(2):461-8. PubMed ID: 7441510
[TBL] [Abstract][Full Text] [Related]
27. Evidence for an involvement of dopamine receptors in the natriuretic response to atrial natriuretic peptide.
Marin-Grez M; Angchanpen P; Gambaro G; Schnermann J; Schubert G; Briggs JP
Klin Wochenschr; 1987; 65 Suppl 8():97-102. PubMed ID: 2955166
[TBL] [Abstract][Full Text] [Related]
28. Effects of harmine on dopamine output and metabolism in rat striatum: role of monoamine oxidase-A inhibition.
Iurlo M; Leone G; Schilström B; Linnér L; Nomikos G; Hertel P; Silvestrini B; Svensson H
Psychopharmacology (Berl); 2001 Dec; 159(1):98-104. PubMed ID: 11797076
[TBL] [Abstract][Full Text] [Related]
29. A comparative study on the synthesis of dopamine in the human, dog and rat kidney.
Soares-da-Silva P; Fernandes MH; Pestana M
Acta Physiol Scand; 1993 Jul; 148(3):347-51. PubMed ID: 8213189
[TBL] [Abstract][Full Text] [Related]
30. Selective inhibition of monoamine oxidase A or B reduces striatal oxidative stress in rats with partial depletion of the nigro-striatal dopaminergic pathway.
Aluf Y; Vaya J; Khatib S; Loboda Y; Finberg JP
Neuropharmacology; 2013 Feb; 65():48-57. PubMed ID: 22982254
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of monoamine oxidase-B by (-)-deprenyl potentiates neuronal responses to dopamine agonists but does not inhibit dopamine catabolism in the rat striatum.
Paterson IA; Juorio AV; Berry MD; Zhu MY
J Pharmacol Exp Ther; 1991 Sep; 258(3):1019-26. PubMed ID: 1679846
[TBL] [Abstract][Full Text] [Related]
32. Modification of the striatal dopaminergic neuron system by carbon monoxide exposure in free-moving rats, as determined by in vivo brain microdialysis.
Hara S; Mukai T; Kurosaki K; Kuriiwa F; Endo T
Arch Toxicol; 2002 Oct; 76(10):596-605. PubMed ID: 12373456
[TBL] [Abstract][Full Text] [Related]
33. Atrial natriuretic factor decreases renal dopamine turnover and catabolism without modifying its release.
Correa AH; Choi MR; Gironacci M; Aprile F; Fernández BE
Regul Pept; 2008 Feb; 146(1-3):238-42. PubMed ID: 17963868
[TBL] [Abstract][Full Text] [Related]
34. Effect of MAO inhibitors on the uptake and metabolism of dopamine in rat and human brain.
Tekes K; Tóthfalusi L; Gaál J; Magyar K
Pol J Pharmacol Pharm; 1988; 40(6):653-8. PubMed ID: 3152003
[TBL] [Abstract][Full Text] [Related]
35. Proceedings: Lack of significance of MAO-B for in vivo deamination of dopamine.
Waldmeier PC; Maître L
Naunyn Schmiedebergs Arch Pharmacol; 1975; 287 Suppl():R2. PubMed ID: 1143400
[No Abstract] [Full Text] [Related]
36. [Effect of benzamide derivatives on rat brain monoamine oxidase activity in vitro].
Gol'dina OA; Zagorevskiĭ VA; Lopatina KI; Sokolova TV; Gankina EM
Biull Eksp Biol Med; 1986 Aug; 102(8):170-2. PubMed ID: 3742029
[TBL] [Abstract][Full Text] [Related]
37. Urodilatin regulates renal dopamine metabolism.
Choi MR; Citarella MR; Lee BM; Kouyoumdzian NM; Rukavina Mikusic NL; Fernández BE
J Nephrol; 2013; 26(6):1042-8. PubMed ID: 23661592
[TBL] [Abstract][Full Text] [Related]
38. Nitrocatechol Derivatives of Chalcone as Inhibitors of Monoamine Oxidase and Catechol-O-Methyltransferase.
Engelbrecht I; Petzer JP; Petzer A
Cent Nerv Syst Agents Med Chem; 2018; 18(2):115-127. PubMed ID: 29697034
[TBL] [Abstract][Full Text] [Related]
39. Different renal effects of two inhibitors of catechol-O-methylation in the rat: entacapone and CGP 28014.
Hansell P; Odlind C; Männistö PT
Acta Physiol Scand; 1998 Apr; 162(4):489-94. PubMed ID: 9597116
[TBL] [Abstract][Full Text] [Related]
40. Monoamine oxidase-A inhibitors and dopamine metabolism in rat caudatus: evidence that an increased cytosolic level of dopamine displaces reversible monoamine oxidase-A inhibitors in vivo.
Colzi A; D'Agostini F; Cesura AM; Borroni E; Da Prada M
J Pharmacol Exp Ther; 1993 Apr; 265(1):103-11. PubMed ID: 8473998
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
